The EU Commission accepts commitments made by a pharmaceutical company to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns (Aspen)

Antitrust: Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns* The European Commission has made commitments offered by Aspen legally binding under EU antitrust rules. Aspen has to reduce its prices in Europe for six critical cancer medicines by 73% on average. In addition, Aspen has to ensure the continued supply of these off-patent medicines for a significant period. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “As a result of today's decision, Aspen has to radically reduce its prices across Europe for six medicines that are essential to treat certain serious forms of blood cancer, including myeloma and leukaemia. Some patients, including young children,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission accepts commitments made by a pharmaceutical company to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns (Aspen), 10 February 2021, e-Competitions February 2021 - II, Art. N° 99249

Visites 234

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues